Attacking a stubborn mutation
An experimental vaccine designed to target the KRAS gene mutation showed promise in preventing pancreatic cancer, according to early trial results. The KRAS mutation appears in most pancreatic cancers and has been one of the hardest targets in medicine. For decades, scientists struggled to find any drug that could block it. New vaccines and other treatments are finally changing that picture.
Pancreatic cancer is one of the deadliest cancers. Most patients are diagnosed at a late stage, when surgery is no longer possible. The five-year survival rate remains low, so doctors are desperate for new tools.
How the vaccine works
The vaccine trains the immune system to recognize cells carrying the mutated KRAS protein. It uses a personalized approach, with each dose built around the patient's own tumor mutations. In the early trial, patients who received the vaccine developed strong immune responses against their cancer cells. Some patients remained free of recurrence longer than expected. The researchers said the results are early but encouraging.
The approach is different from chemotherapy. Chemotherapy attacks all fast-growing cells. The vaccine aims only at cells with the specific mutation, which means fewer side effects.
What comes next
The vaccine is now moving into larger trials that will test it against a placebo. Other teams are testing KRAS vaccines for lung and colon cancer, where the same mutation is common. If the larger trials succeed, the approach could change how high-risk patients are treated. Doctors said patients should not expect the vaccine to be available soon. The trial process takes years, and approval is not guaranteed. But for a cancer with so few options, the early signs offer a new thread of hope.